← Leaderboards
Saul Priceman
Beckman Research Institute/City Of Hope
$1,392,931
Attributed
$2,785,861
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $723K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,785,861 · 1
By mechanism
R01$2,785,861 · 1
Top collaborators
- Lorna Rodriguez-Rodriguez4 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Xiuli Wang$2,702,470
- Terence Marques Williams$5,994,391
- Jianhua Yu$11,234,533
- Christine Brown$5,264,024
- Russell Christian Rockne$4,281,270
Others in their field
Other Rising Stars on “Design”
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Jeffrey Leintz · National Opinion Research Center$38,969,238
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Sabrina Paganoni · Massachusetts General Hospital$30,895,527
Research focus
DesignDoseAntigensAscitesAntitumor EffectCytokineAntitumor ResponseCancer BiomarkersCancer TherapyCar T Cell TherapyCathetersCellsAftercareCharacteristicsChemotherapyChimeric Antigen ReceptorChimeric Antigen Receptor T CellsCitiesClinical CandidateClinical DevelopmentClinical ResearchClinical TranslationClinical TrialsEffective Therapy
Grant awards (4)
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$704,036
R01 · FY2025 · CA
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$668,834
R01 · FY2024 · CA
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$689,955
R01 · FY2023 · CA · contact PI
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$723,036
R01 · FY2022 · CA · contact PI